Bank of New York Mellon Corp has $1.08M stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Bank of New York Mellon Corp grew its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) by 10.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 220,499 shares of the company’s stock after buying an additional 21,231 shares during the period. Bank of New York Mellon Corp’s holdings in Zevra Therapeutics were worth $1,080,000 as of its most recent SEC filing.

A number of other institutional investors have added to or reduced their stakes in ZVRA. Jump Financial LLC acquired a new position in Zevra Therapeutics in the 4th quarter valued at approximately $217,000. Focus Financial Network Inc. ADV acquired a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $141,000. Armistice Capital LLC bought a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $1,755,000. Virtu Financial LLC purchased a new position in shares of Zevra Therapeutics in the fourth quarter valued at $177,000. Finally, Mystic Asset Management Inc. lifted its position in Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock worth $1,545,000 after acquiring an additional 35,514 shares during the period. 35.03% of the shares are owned by institutional investors and hedge funds.

Insider buying and selling

In other Zevra Therapeutics news, Director Thomas Anderson purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average cost of $6.81 per share, with a total value of $68,100.00. Following the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $136,200. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders purchased a total of 22,000 shares of company stock worth $140,340 over the last three months. Insiders own 2.40% of the company’s shares.

Analysts on Wall Street are forecasting an increase

ZVRA has been the subject of several analyst reports. HC Wainwright upped their target price on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Finally, Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Zevra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $21.25, based on data from MarketBeat.com.

See our latest analysis of ZVRA

Zevra Therapeutics stock down 0.5%

ZVRA opened at $8.06 on Friday. The firm has a market cap of $337.34 million, a price-to-earnings ratio of -5.97 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00, and a current ratio of 2.00. The company’s 50-day simple moving average is $7.04 and its 200-day simple moving average is $5.71. Zevra Therapeutics, Inc. it has a twelve month low of $3.89 and a twelve month high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period last year, the company posted ($0.15) earnings per share. Equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.58 EPS for the current fiscal year.

About Zevra Therapeutics

(Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs for the treatment of serious medical conditions in the United States. The company develops its products through the Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is in a Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is in a Phase ½ clinical trial for the treatment of narcolepsy.

Read more

Want to see what other hedge funds own ZVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report).

Get news and reviews for Zevra Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zevra Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.